Lenvatinib use across multiple cancer types: A single-centre evaluation of dosing patterns, tolerability and opportunities for dose optimisation
{{output}}
PurposeLenvatinib is an oral multi-kinase inhibitor prescribed in renal cell carcinoma (RCC), endometrial cancer (EC), hepatocellular carcinoma (HCC), and radioactive iodine-refractory differentiated thyroid cancer (DTC). Lenvatinib is poorly tolerated at the ... ...
